NCT04155541View on ClinicalTrials.gov

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2025

Conditions
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Interventions
DRUG

dacomitinib hydrate

The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.

Trial Locations (1)

Unknown

Pfizer Japan, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04155541 - Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) | Biotech Hunter | Biotech Hunter